R vs S Ketamine: What Actually Matters for Depression Treatment (2026)

Ketamine is a chiral molecule. It exists in two mirror-image forms (the S-enantiomer and the R-enantiomer) and for most of the drug's medical history, the distinction was academic. Anesthesia and pain medicine used racemic (50/50) ketamine. Nobody was asking the question which enantiomer treats depression better.

The question became interesting for two reasons. First, Johnson & Johnson developed esketamine (the S-enantiomer alone) into a nasal spray called Spravato and got FDA approval for treatment-resistant depression in 2019. Second, a series of preclinical papers (mostly from Kenji Hashimoto's group in Japan) suggested R-ketamine might have a stronger and longer-lasting antidepressant effect than S-ketamine, with fewer dissociative side effects. That raised a real clinical question.

Here's what the answer looks like in 2026.

What the molecules actually do differently

Both enantiomers bind NMDA receptors, but not identically.

S-ketamine (esketamine) binds NMDA receptors roughly 3 to 4 times more tightly than R-ketamine. It produces faster onset, stronger dissociation, and more pronounced blood pressure and heart rate changes. The anesthetic effect of a given milligram of racemic ketamine comes mostly from the S half. If you want a rapid, reliable dissociative state, this is the enantiomer that produces it.

R-ketamine (arketamine) has a weaker NMDA affinity but appears to drive downstream BDNF and mTOR signaling more efficiently on a per-NMDA-binding basis. In mouse depression models, R-ketamine produces antidepressant effects at doses too low to cause overt dissociation, and the effect lasts longer than equipotent S-ketamine. Whether that mouse-level finding translates to humans is exactly the question PCN-101 was designed to answer.

Racemic ketamine is the 50/50 mix. Both signals are present. Bioavailability differs by route: roughly 100% IV, 25-32% sublingual, 8-24% for compounded intranasal (Spravato itself reaches ~45-50% via its specialized nasal-spray formulation). IV and sublingual clinical ketamine in the U.S. is almost always racemic.

The PCN-101 trial and why it matters

Perception Neuroscience (a subsidiary of Atai Life Sciences) developed PCN-101, a pure R-ketamine IV formulation, specifically to test Hashimoto's hypothesis in humans. The Phase 2a trial in treatment-resistant depression reported topline results in 2023: PCN-101 failed to separate from placebo on the primary endpoint (MADRS reduction at 24 hours). The secondary endpoints showed numerical but not statistically significant improvement.

That result cooled the R-ketamine excitement considerably. It does not rule out R-ketamine as an antidepressant; trial design, dosing, and patient selection all affect whether a signal emerges. But it means the "R-ketamine is a better antidepressant than S-ketamine" hypothesis does not yet have human Phase 2 evidence behind it. A larger Phase 2b trial is under discussion. As of early 2026, no pure R-ketamine formulation is FDA-approved or clinically available outside trials.

The Spravato picture

Spravato (esketamine nasal spray) is FDA-approved for treatment-resistant depression and, as of 2020, for major depressive disorder with acute suicidal ideation. It's administered in a certified clinical setting under the REMS program: two hours of monitoring after each dose, in a facility that can manage the blood pressure changes and dissociation the drug can produce. That infrastructure is the main reason Spravato is expensive and, for many patients, hard to access. Insurance coverage has expanded since launch but is still uneven. Out-of-pocket cost is typically $600-$900 per session in facility fees alone, on top of the drug itself.

Clinically, Spravato works. The response rate in TRD is real, and for patients who can access it and tolerate the REMS requirements, it's a legitimate option. The practical barriers (the clinic requirement, the cost, the two-hour monitoring) are why at-home racemic sublingual has picked up as much as it has. For a fuller breakdown of nasal-spray ketamine specifically, including REMS logistics, the difference between Spravato and compounded nasal sprays, and what insurance actually covers, see our ketamine nasal spray guide for 2026.

Why most of us still prescribe racemic

At Discreet Ketamine I prescribe racemic sublingual ketamine. A few reasons this remains the standard in off-label psychiatric practice in 2026:

Decades of safety data. Racemic ketamine has been in medical use since 1970. The tolerability profile is well-characterized across age ranges, medical comorbidities, and concurrent medications. Both enantiomers are already in that data.

The mechanism arguments cut both ways. If R-ketamine is what drives BDNF signaling, racemic delivers it. If the S-half contributes to the rapid dissociative shift that opens the therapeutic window, racemic delivers that too. Using pure S-enantiomer alone (Spravato) means intentionally removing the R component.

PCN-101 did not show superiority. The main theoretical argument for pure R-ketamine was that it would produce equivalent antidepressant effect with less dissociation and longer duration. The data did not back that up at the dose tested. Maybe it will with a different dose. For now, "pure R is better" is an open hypothesis, not a clinical finding.

Cost and access. Spravato averages $800 to $1,000 per session including facility fees. Racemic sublingual, delivered at home via compounded pharmacy, runs $250 to $2,200 depending on treatment duration: roughly one-tenth to one-quarter the cost per session. For patients who are appropriate candidates for at-home treatment, the cost-access math is decisive.

What this means for you as a patient

If you are a candidate for Spravato and can access it (meaning you meet the TRD criteria, your insurance covers it, and the clinic requirement fits your life) it is a fully legitimate option.

If Spravato is not accessible (cost, logistics, location), racemic sublingual ketamine through an at-home program is clinically reasonable and supported by a growing body of real-world evidence.

If a clinic is selling you pure R-ketamine as "the better enantiomer" without FDA approval and at a premium, be skeptical. That product doesn't exist through an FDA-approved pathway. It may be available through compounding in some settings, but the clinical evidence doesn't currently justify charging more for it. (Same skepticism applies to any program selling ketamine without a real physician relationship; see How to Buy Ketamine Online Legally for the verification checklist.)

What's actually different in the chair

A practical note. The subjective experience differences between S-weighted dosing (Spravato) and racemic dosing (most off-label ketamine) are smaller than the enantiomer pharmacology would suggest. Patients who switch between them usually describe "a little more floating" versus "a little more reflective," not a fundamentally different experience. At therapeutic doses, both formulations produce the characteristic dissociative state, the neuroplasticity window, and the antidepressant effect.

The more consequential variable in the treatment experience is usually the formulation (rapidly dissolving tablet versus troche), the setting (clinic versus home), the provider you choose (clinical model and physician involvement vary widely between programs), and whether the patient is doing real integration work between sessions. The enantiomer question matters less at the individual patient level than the marketing around it suggests.

Where the field is heading

Three things to watch over the next two to three years:

A larger PCN-101 trial (or a different R-ketamine compound) with adjusted dosing could still find the effect Hashimoto's mouse data predicts.

Next-generation NMDA modulators that aim to decouple the antidepressant effect from the dissociation entirely (aptinurin, rapastinel-family compounds) are in various phases of development. They are not ketamine, but they are targeting the same pathway.

Intranasal racemic ketamine (not Spravato; a different delivery of the standard racemic mix) is in late-stage development and would bridge some of the Spravato-vs-sublingual divide if it reaches market.

For the moment, in 2026 clinical practice, racemic ketamine delivered via the right formulation, in the right setting, with real integration work, is the default answer for most patients who are candidates for ketamine therapy at all.

Frequently Asked Questions

What's the difference between R-ketamine and S-ketamine?

Ketamine is a chiral molecule with two mirror-image forms. S-ketamine (esketamine) binds NMDA receptors 3-4× more tightly, producing faster onset, stronger dissociation, and more pronounced cardiovascular effects. R-ketamine (arketamine) has weaker NMDA affinity but appears to drive BDNF and mTOR signaling more efficiently per binding event, with longer-lasting antidepressant effects in animal models. Whether that animal-model finding translates to humans is still an open question after the PCN-101 Phase 2a trial in 2023 failed to show statistical superiority over placebo.

Is racemic ketamine the same as ketamine?

Yes. "Racemic ketamine" is the standard 50/50 mixture of S-ketamine and R-ketamine. When clinicians say "ketamine" without further qualification (whether for IV infusions, sublingual troches, or anesthesia) they almost always mean the racemic mix. It's been in continuous medical use since 1970 and has decades of safety data behind it.

Is Spravato better than racemic ketamine for depression?

Not in any clear-cut way. Spravato is FDA-approved for treatment-resistant depression and major depressive disorder with acute suicidal ideation, while racemic sublingual ketamine is prescribed off-label. The clinical effects are comparable in real-world data. Spravato's main practical disadvantage is cost ($600-900/session) and the REMS-required two-hour clinic monitoring. Racemic at-home ketamine is far cheaper and more accessible, but lacks FDA approval for psychiatric indications.

What is arketamine?

Arketamine is the R-enantiomer of ketamine: the mirror-image half of the molecule that binds NMDA receptors more weakly than the S half. It's been hypothesized to have stronger and longer-lasting antidepressant effects than S-ketamine, with fewer dissociative side effects. The PCN-101 Phase 2a trial in 2023 was designed to test this in humans and did not show statistical separation from placebo. As of 2026, no pure arketamine formulation is FDA-approved or clinically available outside trials.

Why isn't pure R-ketamine FDA-approved?

Because the human clinical trial data doesn't yet support it. The PCN-101 Phase 2a trial in 2023 (designed to test pure R-ketamine in treatment-resistant depression) did not show statistical superiority over placebo on the primary endpoint. That doesn't disprove R-ketamine as an antidepressant, but it means the regulatory bar for approval hasn't been cleared. A larger Phase 2b trial with adjusted dosing is under discussion.

Which type of ketamine is best for depression?

For most patients, the practical answer in 2026 is racemic sublingual ketamine through an at-home program; it's clinically reasonable, cost-effective, and supported by growing real-world evidence. If you have insurance coverage and meet TRD criteria, Spravato (S-ketamine nasal spray) is a fully legitimate alternative. Pure R-ketamine isn't a clinically available option yet. The more impactful variables are formulation, setting, provider quality, and integration work, not which enantiomer you receive.

Is S-ketamine the same as Spravato?

Functionally yes: Spravato is the brand name for esketamine, which is pure S-ketamine. Spravato specifically refers to Janssen's FDA-approved nasal spray formulation, administered in a certified clinical setting under the REMS program. "S-ketamine" or "esketamine" can also refer to the same molecule in research or compounded contexts, but Spravato is the only FDA-approved esketamine product on the U.S. market.

References

1. Yang C, Shirayama Y, Zhang JC, et al. R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry. 2015;5(9):e632. PubMed: 26327690 · Free full text The foundational Hashimoto-group preclinical paper showing R-ketamine has greater and longer-lasting antidepressant effects than S-ketamine in mouse models, with BDNF-TrkB signaling driving the response. The basis for the body's "Hashimoto's hypothesis" framing and the rationale that drove PCN-101 development.

2. Daly EJ, Trivedi MH, Janik A, et al. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2019;76(9):893-903. PubMed: 31166571 Establishes Spravato (S-ketamine nasal spray) as FDA-approved for TRD as add-on to oral antidepressant. The basis for the body's Spravato regulatory and clinical claims.

3. Fu DJ, Ionescu DF, Li X, et al. Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I). J Clin Psychiatry. 2020;81(3):19m13191. PubMed: 32412700 Phase 3 trial supporting Spravato's broader 2020 indication for major depressive disorder with acute suicidal ideation, referenced in the body.

4. Peltoniemi MA, Hagelberg NM, Olkkola KT, Saari TI. Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy. Clin Pharmacokinet. 2016;55(9):1059-1077. PubMed: 27028535 Standard pharmacokinetics review across routes. Source for the bioavailability comparison (~100% IV, 25-32% sublingual, 8-24% compounded intranasal vs ~45-50% Spravato) referenced in the body.

5. Sanacora G, Frye MA, McDonald W, et al. A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. JAMA Psychiatry. 2017;74(4):399-405. PubMed: 28249076 APA-task-force consensus on screening, dosing, and monitoring across clinical ketamine use, including the framework distinguishing FDA-approved esketamine from off-label compounded racemic ketamine.

Note: PCN-101 Phase 2a topline results (Perception Neuroscience, 2023) were reported via company press release (ClinicalTrials.gov NCT05203237). No peer-reviewed publication of the trial results was available at the time of writing.

Ready to start?

If you want to know whether at-home racemic ketamine therapy is appropriate for your situation, the five-minute eligibility check will tell you quickly. If Spravato or another option would be a better fit, I will say so.

Discreet Ketamine provides at-home ketamine therapy to residents of Florida and New Jersey. All treatments are supervised by Dr. Ben Soffer, a board-certified physician. Compounded racemic ketamine is prescribed off-label for depression, anxiety, PTSD, and chronic pain; it is not FDA-approved for these indications.